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Dietary Recommendations for Adults With Psoriasis
or Psoriatic Arthritis From the Medical Board
of the National Psoriasis Foundation
A Systematic Review
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Alice Gottlieb, MD, PhD; Lawrence J. Green, MD; Johann E. Gudjonsson, MD, PhD; John Koo, MD;
Mark Lebwohl, MD; Wilson Liao, MD; Arthur M. Mandelin II, MD, PhD; Joseph A. Markenson, MD;
Nehal Mehta, MD, MSCE, FAHA; Joseph F. Merola, MD, MMSc; Ronald Prussick, MD; Caitriona Ryan, MD, FAAD;
Sergio Schwartzman, MD; Evan L. Siegel, MD; Abby S. Van Voorhees, MD; Jashin J. Wu, MD;
April W. Armstrong, MD, MPH
IMPORTANCE Psoriasis is a chronic, inflammatory skin disease and has significant associated
morbidity and effect on quality of life. It is important to determine whether dietary
interventions help reduce disease severity in patients with psoriatic diseases.
OBJECTIVE To make evidence-based dietary recommendations for adults with psoriasis
and/or psoriatic arthritis from the Medical Board of the National Psoriasis Foundation.
EVIDENCE REVIEW We used literature from prior systematic reviews as well as additional
primary literature from the MEDLINE database from January 1, 2014, to August 31, 2017, that
evaluated the impact of diet on psoriasis. We included observational and interventional
studies of patients with psoriasis or psoriatic arthritis. The quality of included studies was
assessed using the Newcastle-Ottawa scale for observational studies and the Cochrane Risk
of Bias Tool for interventional studies. We made evidence-based dietary recommendations,
which were voted on by the National Psoriasis Foundation Medical Board.
FINDINGS We identified 55 studies meeting the inclusion criteria for this review. These studies
represent 77 557 unique participants of which 4534 have psoriasis. Based on the literature,
we strongly recommend dietary weight reduction with a hypocaloric diet in overweight and
obese patients with psoriasis. We weakly recommend a gluten-free diet only in patients who
test positive for serologic markers of gluten sensitivity. Based on low-quality data, select
foods, nutrients, and dietary patterns may affect psoriasis. For patients with psoriatic
arthritis, we weakly recommend vitamin D supplementation and dietary weight reduction
with a hypocaloric diet in overweight and obese patients. Dietary interventions should always
be used in conjunction with standard medical therapies for psoriasis and psoriatic arthritis.
CONCLUSIONS AND RELEVANCE Adults with psoriasis and/or psoriatic arthritis can supplement
their standard medical therapies with dietary interventions to reduce disease severity. These
dietary recommendations from the National Psoriasis Foundation Medical Board will help
guide clinicians regarding the utility of dietary interventions in adults with psoriatic diseases.
JAMA Dermatol. 2018;154(8):934-950. doi:10.1001/jamadermatol.2018.1412
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P soriasis is a chronic, inflammatory skin disease that affects3.2% of US adults1 and has a substantial effect on quality oflife.2,3 In addition to skin manifestations, psoriasis is asso-
ciated with many comorbidities including psoriatic arthritis, cardio-
metabolic disease, gastrointestinal disease, and mood disorders.2
Various medical therapies exist for psoriatic diseases including topi-
cal agents, phototherapy, oral medications, and biologics.3 Prescrip-
tion drugs and medical phototherapy have undergone rigorous ef-
ficacy and safety evaluation via clinical trials and long-term registries.
Regardless of patients’ perspectives on established medical thera-
pies, nearly all patients seek to understand how diet affects their pso-
riatic disease.4
Specifically, most patients deem dietary interventions to be rel-
evant to their overall psoriatic disease management; however, diet
is rarely discussed during clinical visits.4,5 Furthermore, studies show
that patients with psoriasis are highly motivated to carry out di-
etary changes because these interventions are perceived to be natu-
ral, safe, and patient initiated.5,6 However, most patients and clini-
cians lack knowledge on how well dietary interventions work because
few articles exist that summarize literature on psoriasis and diet.4,7-10
Overall, there is a critical lack of evidence synthesis on the
relationship between psoriatic diseases and diet. This literature
gap speaks to the need for evidence-based dietary recommenda-
tions that are accessible to clinicians and patients. In this article,
we present evidence synthesis from a systematic review that
answers key questions on the role of dietary interventions in pso-
riatic diseases. Based on this systematic review, we present
evidence-based recommendations from the National Psoriasis
Foundation (NPF) Medical Board on the role of dietary interven-
tions in psoriatic diseases.
Methods
Systematic Review
To explore the current evidence relating to diet and psoriasis, we lev-
eraged prior reviews that used Cochrane Central Register of Con-
trolled Trials in the Cochrane Library, MEDLINE, and EMBASE4,7-10
and performed additional systematic review synthesizing primary
literature from 2014 through 2017 from MEDLINE. For evaluation
of additional primary studies from January 1, 2014, to August 31, 2017,
we used the following search criteria in MEDLINE: (“Psoriasis” [medi-
cal subject heading {MeSH}] AND “Diet, Food, and Nutrition” [MeSH])
OR “Psoriasis/diet therapy” [MeSH]. Through reading of primary lit-
erature, we identified additional studies not identified through the
MEDLINE search (Figure).5,11,12
This review included observational and interventional studies
(controlled and uncontrolled). The studies must have met the fol-
lowing inclusion criteria: study participants must have psoriasis
and/or psoriatic arthritis; studies must use a dietary or nutritional
intervention or examine food intake and/or dietary patterns;
outcomes must include the development of psoriasis, psoriatic dis-
ease severity, or patient-reported effects of diet on disease sever-
ity. We excluded case reports, case series, review articles, non-
English language studies, and studies exclusively evaluating alcohol
as a dietary component.
Two authors (A.R.F. and A.W.A.) read reference abstracts to
determine eligibility based on inclusion and exclusion criteria.
Selected studies underwent full-text review. Two of us (A.R.F. and
A.W.A.) independently extracted the data. We performed quality
assessment using the Newcastle-Ottawa scale for observational
studies and the Cochrane Risk of Bias Tool for interventional stud-
ies. The quality of uncontrolled interventional studies was not
assessed.
Recommendation Development
Recommendations were developed using established guidance by
Robinson et al13 to determine the strength of recommendations and
the level of supporting evidence. The findings from the systematic
review and the proposed recommendations were reviewed and ap-
proved by majority vote by the NPF Medical Board.
Briefly, level of evidence determines the strength of
recommendation13:
• Level of evidence “A” refers to high-quality, patient-oriented evi-
dence, which leads to a “strong recommendation” (strength of
recommendation 1).
• Level of evidence “B” refers to limited-quality, patient-oriented evi-
dence, which leads to a “weak recommendation” (strength of rec-
ommendation 2A).
• Level of evidence “C” refers to low-quality evidence, which leads
to a “weak recommendation” (strength of recommendation 2B).
Results of the Systematic Review
and NPF Recommendations
Fifty-five studies meet the inclusion criteria for this systematic re-
view (Figure). These studies represent a total of 77 557 unique par-
ticipants of which 4534 have psoriasis. Although a small number of
pediatric patients are included in some studies, the data are insuf-
ficient to make recommendations for pediatric psoriasis. Study char-
acteristics and outcome data are summarized in Table 15,27,29,51,60,61
and Table 2.11,12,14-16,19-28,30,33-41,44-50,52,54-58,62,63,66-75 Quality as-
sessment results for observational studies are included in Table 1;
results for interventional studies are reported in the eTable in the
Supplement. Dietary recommendations are summarized in
Table 3.13-17,19-23,45,60-63
Key Points
Question What dietary interventions help adult patients with
psoriasis and/or psoriatic arthritis reduce their disease severity?
Findings In this systematic review of 55 studies and 4534 patients
with psoriasis, we identify the strongest evidence for dietary
weight reduction with a hypocaloric diet in overweight and obese
patients with psoriasis. The utility of gluten-free diet and
supplementation with vitamin D varies by subpopulations of
adults with psoriatic diseases, and evidence is low for the utility of
specific foods, nutrients, and dietary patterns in reducing psoriatic
disease activity.
Meaning Adults with psoriasis and/or psoriatic arthritis can
supplement their medical therapies with dietary interventions to
reduce disease severity.
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Question 1: Are Gluten-Free Diets Helpful in Psoriasis?
Psoriasis is associated with an increased risk of several autoim-
mune diseases; this includes a greater than 2-fold increased fre-
quency of celiac disease.7 Celiac disease is characterized by a small
intestinal inflammatory response to dietary gluten. Serum antibod-
ies indicating gluten sensitivity (IgG tissue transglutaminase, IgA en-
domysial antibody) are used to screen for celiac disease. Definitive
diagnosis of celiac disease is made by demonstration of character-
istic findings on duodenal biopsy. Of note, controversy exists re-
garding the existence of gluten sensitivity (characterized by posi-
tive serologic markers) in the absence of celiac disease.
Patients with psoriasis have an increased risk of positivity for
serologic markers of gluten sensitivity, and higher antibody levels
are associated with greater psoriasis severity.7 Some patients with
psoriasis have markers of gluten sensitivity with normal
duodenal biopsy results.7,14 Therefore, some patients with psoria-
sis seem to have gluten sensitivity in the absence of celiac disease.
Based on the available literature, a gluten-free diet may be help-
ful in select patients with psoriasis.14-16 In patients with confirmed
celiac disease, a gluten-free diet not only ameliorates gastrointes-
tinal symptoms but also reduces psoriasis severity.16 In patients who
test positive for serologic markers of gluten sensitivity, a gluten-free
diet leads to significant improvements in both clinical psoriasis se-
verity and skin biopsy findings after 3 months.14,15 Histologically, a
decrease in the number of inflammatory and proliferating cells is seen
in psoriatic plaques.15 A majority of these patients experience wors-
ening of disease after resuming a regular diet.14 Additionally, among
patients who test positive for serologic markers of gluten sensitiv-
ity, a gluten-free diet seems to be beneficial regardless of duodenal
biopsy results.14-16 In contrast, studies show that a gluten-free diet
is not helpful in patients with psoriasis who test negative for sero-
logic markers of gluten sensitivity.14,15
Recommendation 1: Gluten-Free Diet in Psoriasis
• In adults with psoriasis with confirmed celiac disease, we strongly
recommend a gluten-free diet.16,17
• This strong recommendation (strength 1) is based on level A
evidence.
• Only in adults with psoriasis who test positive for serologic
markers of gluten sensitivity, we recommend a 3-month trial of a
gluten-free diet as an adjunctive intervention to standard medi-
cal therapies for psoriasis.
• We do not recommend universal screening for serologic markers
of gluten sensitivity among adults with psoriatic diseases
because of a high rate of false-positive results.18 Based on
recommendations from the American College of Gastroenterol-
ogy, patients who are candidates for screening include those
with a first-degree relative with celiac disease or those with
active gastrointestinal symptoms.17
• This weak recommendation (strength 2A) is based on level B
evidence; limitations include a lack of randomization, small
control groups, no reporting of between-group comparisons,
and study-related bias.14-16
Question 2: What Is the Association of Dietary Weight
Reduction With Psoriasis?
There is a well-established link between obesity and psoriasis.2,9 Ex-
cess body weight is associated with increased psoriasis incidence,
higher psoriasis severity, and reduced response to psoriasis
treatments.2,4,9 These associations may be mediated by the proin-
flammatory effects of body fat.4
Dietary weight reduction refers to weight loss as a result of di-
etary interventions and not from exercise or surgery. From the litera-
ture on dietary weight reduction, we learn that weight reduction with
a hypocaloric diet—one that delivers less energy per day than an in-
dividual’s expenditure—can be helpful in patients with psoriasis who
are overweight or obese, defined as a body mass index (BMI, calcu-
lated as weight in kilograms divided by height in meters squared) of
25 or more. In these patients, a hypocaloric diet leads to significant
improvements in psoriasis severity,19-22 dermatology quality of life,21,23
and weight loss,19-23 compared with patients consuming a regular diet.
The duration of beneficial dietary interventions ranges from 16 weeks
to 6 months, and improvements in skin disease severity and
dermatology quality of life can be maintained after 1 year.24 The en-
ergy content of hypocaloric diets ranges from 800 to 1400 kcal per
day.19-23 Dietary weight reduction is beneficial in conjunction with stan-
dard psoriasis treatments including biologic therapy,19,22,23
cyclosporine,20-22 methotrexate,21-23 acitretin,22 phototherapy,22 and
various topical therapies.22 Further support comes from 2 recent sys-
tematic reviews, 1 with a meta-analysis, that demonstrate significant
benefit of weight loss with a hypocaloric diet in overweight and obese
patients with psoriasis.4,9 Uncontrolled data also support a hypoca-
loric diet in these patients for improvement in skin disease severity,
dermatology quality of life, and weight loss.24-26
In 1 randomized clinical trial (RCT), after maintaining remission for
12 weeks during methotrexate therapy, patients discontinued metho-
trexate and were randomized to hypocaloric vs regular diet. The hy-
pocaloric diet group had lower psoriasis severity scores compared with
the regular diet group, but this was not statistically significant. Thus,
diet alone may not be sufficient to maintain psoriasis remission.27
Limited data exist regarding other diets in patients with psoria-
sis. Ornish and South Beach diets helped patients with psoriasis
achieve weight loss in an RCT, but their long-term benefit on pso-
riasis severity is uncertain.28
Figure. Diet and Psoriasis Literature Search and Screening Results
63 Full-text articles assessed for eligibility
48 Records identified through PubMed search
42 Additional records identified from prior systematic reviews
3 Additional records identified from plain language search
93 Records screened
55 Studies included in the systematic review
30 Records excluded after reviewing
abstracts
8 Full-text articles excluded
6 Outcome was not disease severity
1 Intervention was not nutritional
1 Review article
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No significant association between vitamin D intake (dietary,
supplementary, total) and incident psoriasis. RR of psoriasis in
patients taking varying levels of vitamin D vs those taking
300-399 IU/d of vitamin D: 0.60 (95% CI, 0.24-1.50) for
>1000 IU/d, 1.23 (95% CI, 0.80-1.87) for 800-999 IU/d,
1.05 (95% CI, 0.81-1.36) for 400-799 IU/d, 0.98





















use over 30 d, PASI,
DLQI
Patients with psoriasis vs controls: Compared with controls,
higher proportion of patients with psoriasis used supplements
(72.5% vs 25.4%; P = .01). Among patients with psoriasis: no
significant difference in psoriasis severity or dermatology
quality of life between patients with psoriasis using and not
using supplements or between those using different
supplements. Among patients with psoriasis, most common
supplements were multivitamins (26.8%), folic acid (21.7%),























Patients with psoriasis vs controls: Compared with controls,
patients with psoriasis had lower adherence to the
Mediterranean diet (P < .001). Compared with controls, a
smaller proportion of patients with psoriasis consumed EVOO as
main lipid, fruit ≥3 servings/d, fish or seafood ≥3/wk, tree nuts
≥3/wk. Among patients with psoriasis: Lower psoriasis severity
was associated with consuming EVOO as main lipid, vegetables
≥2 servings/d, fruits ≥3 servings/d, legumes ≥3/wk, fish or
seafood ≥3/wk, tree nuts ≥3/wk, sofrito sauce ≥2/wk
(P < .009). Adherence to Mediterranean diet and consuming
EVOO were predictors of lower psoriasis severity (P = .007 and















7-d food record to
measure energy and
nutrient intake, PASI
Patients with psoriasis vs controls: Compared with controls,
patients with psoriasis had higher consumption of total and
simple carbohydrates, total fat, PUFAs, ω-6:ω-3 PUFA ratio,
cholesterol; lower consumption of protein, complex
carbohydrates, MUFAs, ω-3 PUFAs, fiber (P < .034). Among
patients with psoriasis: Higher MUFA consumption was a major
predictor of lower psoriasis severity (P < .001). Lower psoriasis
severity was associated with lower total energy, saturated fatty
acids, total PUFAs, ω-6 PUFAs, ω-6:ω-3 PUFA ratio, simple
carbohydrates and with higher ω-3 PUFAs, MUFAs, fiber,






































Patients with psoriasis vs controls: Compared with controls,
patients with psoriasis had lower daily intake of sugar, whole
grain fiber, dairy products, calcium (P < .001); higher daily
intake of fruits/vegetables/legumes (P = .007). Among patients
with psoriasis (psoriasis patient perceptions): Triggers that
worsen psoriasis: sugar (13.8%), alcohol (13.6%), tomato
(7.4%), gluten (7.2%), dairy (6%). Items that may improve
psoriasis: supplements (unspecified) (35.1%), vegetables
(26.5%), fruits (21.8%), water (11.2%), fish (9.2%). Dietary
reductions associated with patient-reported psoriasis
improvement: alcohol (53.8%), gluten (53.4%), nightshades
(52.1%), junk foods (50.4%), white flour products (49.9%).
Dietary additions associated with patient-reported psoriasis
improvement: fish oil/ω-3 (44.6%), vegetables (42.5%), oral
vitamin D supplementation (41%), probiotics (40.6%), organic
foods (38.4%), fruits (34.6%). Forty percent of patients with
psoriasis had tried special diet for psoriasis; patients reported




















Psoriasis patient perceptions: body weight can influence
psoriasis severity (19%), foods can improve psoriasis (38%)
(fruits and vegetables 60%, fish 10%), foods can worsen
psoriasis (46%) (sausages 20%, dairy products 8%, tomatoes
8%, spicy food and chocolate 7%, fried food 5%), diet regimen
can improve psoriasis (62%). Compared with normal weight
patients with psoriasis, significantly more overweight/obese
patients thought body weight can influence psoriasis severity
(P < .003) and diet regimen can improve psoriasis (P < .04).
4
Abbreviations: BMI, body mass index; DLQI, Dermatology Life Quality Index;
EVOO, extra virgin olive oil; MUFA, monounsaturated fatty acid; NHANES,
National Health and Nutrition Examination Survey; NPF, National Psoriasis
Foundation; PASI, Psoriasis Area and Severity Index; PREDIMED, Prevención
con Dieta Mediterránea; PUFA, polyunsaturated fatty acid; RR, relative risk.
a Quality assessed using Newcastle-Ottawa scale for case-control and cohort
studies (maximum score of 9), modified Newcastle-Ottawa scale for
cross-sectional studies (maximum score of 8).
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Table 2. Interventional Studies on the Effects of Gluten-Free Diet, Dietary Weight Reduction,
and Dietary Supplements on Psoriasis and Psoriatic Arthritis (PsA)
Source;










Psoriasis, some with PsA,
age 18-70 y, stable
psoriasis treatment for
at least 1 mo. Group 1:
elevated IgA AGA and/or
IgG AGA, n = 33. Group
2: normal IgA AGA and
IgG AGA, n = 6.
3-mo gluten-free






Between-group comparisons were not reported. Mean (SD)
psoriasis severity (PASI) improved in group 1 from 5.4 (4.5) to
3.6 (3.0) after gluten-free diet (P < .001); no improvement in
group 2 from 8.9 (6.4) to 10.2 (7.9) (P = .47). In group 1, PASI
improved in similar proportion of patients with psoriasis with
normal and abnormal duodenal biopsy (75% and 67%,
respectively). In group 1, 24% of patients decreased their
psoriasis treatment during gluten-free diet and 0% increased
treatment; in group 2, 0% decreased and 33% increased
treatment. After resuming regular diet, 60% of group 1 needed










Psoriasis, some with PsA,
age 18-70 y, stable
psoriasis treatment for
at least 1 mo. Group 1:
elevated IgA AGA and/or
IgG AGA, n = 31. Group
2: normal IgA AGA and









Between-group comparisons were not reported. Group 1:
significant reduction in No. of CD4+ T lymphocytes in involved
epidermis (P = .03), No. of Ki67+ (proliferating) cells in
involved (P = .008) and noninvolved (P = .04) dermis, % tTG+
area in involved dermis (P = .008). Group 1: no significant
change in
No. of CD4+ T lymphocytes in involved dermis and noninvolved
epidermis and dermis, % CD1+ (Langerhans cells) area in
involved and noninvolved epidermis and papillary dermis, %
CD31/Q-Bend+ (endothelial cells) area in involved and
noninvolved dermis, % Ki67+ (proliferating cells) area in
involved and noninvolved epidermis, % tTG+ area in non









psoriasis, some with PsA,




therapy. N = 9.
6-mo gluten-free
diet
None Uncontrolled data: Gluten-free diet led to significant
improvement in psoriasis severity (PASI 50 or PASI 75) in all
patients after 3 mo; the level of improvement was maintained











>10, age 18-80 y, BMI
>25, not achieving
clearance with systemic
therapy after 4 wk
(continued during
study). Intervention:













Compared with controls, hypocaloric diet group had
significantly greater reduction in psoriasis severity and body
weight. Specifically, median PASI reduction, 48.0% (95% CI,
33.3%-58.3%) hypocaloric diet group vs 25.5% (95% CI,
18.2%-33.3%) controls (P = .02). PASI 50, 49.7% (95% CI,
41.7%-57.6%) of hypocaloric diet group vs 34.2% (95% CI,
26.7%-41.7%) of controls (P = .006). Median BMI reduction,
3.0% (95% CI, 2.4%-3.9%) hypocaloric diet group vs 1.9%





















Compared with controls, hypocaloric diet group had
significantly greater achievement of improved arthritis disease
severity and significantly greater weight loss. Specifically,
achievement of MDA, 43% of hypocaloric diet group vs 35% of
controls (HR, 1.85; 95% CI, 1.02-3.35; P = .04). Weight loss
>5% more likely in hypocaloric diet group vs controls
(HR, 3.23; 95% CI, 1.93-5.39; P < .001). Achievement of MDA










PASI ≥10, BSA ≥10%,
age ≥18 y, BMI 30-45.
Intervention: n = 30;















Compared with controls, hypocaloric diet group had
significantly greater improvement in psoriasis severity and
significantly greater weight loss. Specifically, PASI 75, 67% of
hypocaloric diet group vs 29% of controls (P < .001). PASI 50,
87% of hypocaloric diet group vs 48% of controls (P < .001).
Mean (SD) PASI at week 24, 2.5 (6.3) hypocaloric diet group vs
8.1 (5.4) controls (P < .001). Mean (SD) BSA at week 24, 2.9%
(4.4%) hypocaloric diet group vs 7.5% (4.9%) controls
(P < .001). Mean (SD) weight loss, 7.0 (3.5) kg hypocaloric diet










≥18 y, BMI >30,
receiving stable systemic
treatment for at least 5
mo (continued during
study). Intervention:





Compared with controls, hypocaloric diet group had lower
psoriasis severity (PASI; P < .05), better dermatology quality of
life (DLQI; P < .05), and lower body weight (P < .05) after 6
mo. No significant difference between hypocaloric diet and
control groups in itch severity (VAS itch score) after 6 mo
(continued)
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Table 2. Interventional Studies on the Effects of Gluten-Free Diet, Dietary Weight Reduction,
and Dietary Supplements on Psoriasis and Psoriatic Arthritis (PsA) (continued)
Source;











>10 or >5 and
uncontrolled by topical
therapy, age ≥18 y, BMI
≥30, receiving
methotrexate and
obtained PASI 75 for 12
wk. Intervention: n = 22;














No significant differences between hypocaloric diet and control
groups in psoriasis severity (PASI) over 24-week diet or
12-week follow-up. Mean (SD) weight loss at 12 wk, 9% (2.4%)
hypocaloric diet group (P < .05), maintained at 24 wk














≥10, age ≥18 y, BMI >25,
eligible for
phototherapy.
Intervention: n = 20;
control: n = 10.
12-wk Ornish diet
(vegetarian, low fat,
n = 10) or South
Beach diet (low
carbohydrate,







No significant differences between Ornish diet, South Beach
diet, and control groups in improvement in psoriasis severity.
Specifically, PASI 75, 83% of Ornish diet group, 56% of South
Beach diet group, 38% of controls (P = .30). Mean PASI
improvement, 78% Ornish diet group, 72% South Beach diet
group, 71% controls. Mean weight loss, 8% Ornish diet group,










age >18 y, BMI 25-35,
receiving biologic
therapy. Intervention:




Usual diet Compared with controls, hypocaloric diet group had
significantly greater reduction in psoriasis severity and body
weight. Specifically, PASI 75, 85.9% of hypocaloric diet group
vs 59.4% of controls (P < .001). Mean (SD) weight change,









Plaque psoriasis, age >18
y, BMI >27, stable
psoriasis treatment ≥3
mo before study.
Intervention: n = 30;






No significant difference between hypocaloric diet and control
groups in psoriasis severity after 16 wk. Specifically, mean
between-group difference in PASI, −2.0 (95% CI, −4.1 to 0.1)
in favor of hypocaloric diet group (P = .06). Compared with
controls, hypocaloric diet group had significantly better
dermatology quality of life and significantly greater weight loss
after 16 wk. Specifically, mean between-group difference in
DLQI, −2.0 (95% CI, −3.6 to −0.3) in favor of hypocaloric diet
group (P = .02). Mean between-group difference in weight loss
15.4 (95% CI, 12.3 to 18.5) kg in favor of hypocaloric diet
group (P < .001). PASI improvement correlated with weight









>30%, duration >10 y,
age 40-65 y.
Intervention: n = 42;







Between-group comparisons were not reported. “Significant
improvement of clinical findings” in hypocaloric diet group
(effect measures not reported). Body weight did not change







Plaque psoriasis, age >18
y, BMI >27, stable
psoriasis treatment ≥3





period with 1 meal




None Uncontrolled data: Hypocaloric diet resulted in significant
improvement in psoriasis severity and dermatology quality of
life and significant weight loss after 16 wk; changes in psoriasis
severity and dermatology quality of life were maintained after
maintenance period. Specifically, mean PASI change, −2.3
(95% CI, −3.1 to −1.5) at week 16, −2.9 (95% CI, −3.9 to −1.9)
at week 64. Mean DLQI change, −2.3 (95% CI, −3.2 to −1.4) at
week 16 to −1.9 (95% CI, −3.0 to −0.9) at week 64. Mean
weight loss, 15.0 (95% CI, 13.4 to 16.6) kg at week 16,
















None Uncontrolled data: Hypocaloric diet resulted in 30.9%
improvement in psoriasis severity (PASI; P < .05), 62.5%
improvement in dermatology quality of life (DLQI; P < .01),
and 9.6% weight loss (P < .01) after 12 wk










PsA, age >18 y, not
receiving biologics or
oral steroids.
Intervention: n = 73;
control: n = 72.
24-wk
supplementation
with ω-3 fatty acids:
6 capsules
containing 1.5 g







No significant differences between ω-3 and control groups in
changes in any clinical outcome measures of skin or arthritis
disease severity. Compared with ω-6 group, ω-3 group had
greater reduction in the use of NSAIDs (P = .04) and
paracetamol (P = .04). Significant reductions in tender joint
count, DAS28-CRP, LEI, SPARCC, PASI in ω-3 group; significant











>8%, age 19-74 y, no
systemic treatment 4 wk
before study, topical
treatments continued.
Intervention: n = 72;
control: n = 73.
4-mo
supplementation
with ω-3 fatty acids:
6 fish oil capsules
containing 3.1 g
















No significant differences between ω-3 and control groups in
changes in psoriasis severity. Specifically, mean target plaque
score (scaling, erythema, infiltration) changed identically
between ω-3 and control groups. Mean PASI did not change
significantly in either group. Patient-reported psoriasis severity
score (redness, scaling, itching, effect on daily living) did not
change significantly in either group.
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Table 2. Interventional Studies on the Effects of Gluten-Free Diet, Dietary Weight Reduction,
and Dietary Supplements on Psoriasis and Psoriatic Arthritis (PsA) (continued)
Source;

















n = 26; control: n = 25.
7-mo
supplementation















No significant differences between ω-3 and control groups in
psoriasis severity (percentage area involved, redness, scaling,










Polyarticular PsA (5 or
more swollen joints), no
intra-articular
glucocorticoids or
change in DMARDs for 4
wk before study, NSAIDs
and DMARDs continued.
Intervention: n = 22;
control: n = 21.
14-d
supplementation
with ω-3 fatty acids:
30 mL seal oil
containing 2.4 g














No significant differences between ω-3 and ω-6 groups in
clinical outcome measures of skin or arthritis disease severity
at the end of supplementation or after the follow-up period.
Patient’s global assessment VAS improved significantly at week
6 in ω-3 group (P < .01). No. of swollen joints decreased at
week 6 in ω-3 group (P < .05). No. of tender joints decreased












PsA, age 18-76 y,
NSAID/paracetamol dose
stable for 1 mo before
study. Intervention:
n = 19; control: n = 19.
9-mo
supplementation





240 mg EPA, 132
mg DHA, vitamin E
daily. Subsequently
crossed over to








No significant differences between ω-3 and control groups in
arthritis disease severity (grip strength, No. of active joints,
Ritchie articular index, duration of morning stiffness, NSAID
intake) or skin disease severity (BSA, investigator disease










Psoriasis, age 17-72 y,
no topical steroids 2 mo
before study.
Intervention: n = 15;
control: n = 15.
8-wk
supplementation
with ω-3 fatty acids:
10 fish oil capsules
(MaxEPA)
containing 1.8 g
EPA, 1.2 g DHA,







Between-group comparisons were not reported. Clinical score
(erythema, infiltration, desquamation) and BSA did not change














Intervention: n = 14;
control: n = 14.
12-wk
supplementation
with ω-3 fatty acids:
10 fish oil capsules
(MaxEPA)
containing 1.8 g






Compared with controls, ω-3 group had significantly greater
improvement in itch at week 8 and erythema at weeks 8 and
12 (P < .05). No significant differences between groups in













systemic treatment for 4
wk or topical treatment
for 2 wk before study.
Intervention: n = 10;
control: n = 15.
9-wk
supplementation
with ω-3 fatty acids:
30 fish oil capsules
(Max-EPA)
containing 5.4 g














No significant differences between ω-3 and control groups in
psoriasis improvement after topical treatment or in time to
worsening of psoriasis to pretreatment severity. Specifically,
equivalent improvement in psoriasis severity (scale, erythema,
thickness, BSA) between groups after 3-wk topical steroid
treatment. Mean (SD) time from termination of topical steroid
treatment to worsening of psoriasis to pretreatment severity












adults, skin type II or III,
no systemic treatment
for 4 wk or topical
treatment for 2 wk
before study.
Intervention: n = 9;
control: n = 11.
15-wk
supplementation
with ω-3 fatty acids:
20 fish oil capsules
(Max-EPA)
containing 3.6 g












Compared with controls, ω-3 group had significantly greater
improvement in psoriasis severity. Specifically, change from
baseline in scale, −35% ω-3 group vs 9% controls (P = .008);
erythema, −43% ω-3 group vs 0% controls (P = .02); thickness,
−48% ω-3 group vs 7% controls (P = .006); BSA, −46% ω-3
group vs 32% controls (P < .001).
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Table 2. Interventional Studies on the Effects of Gluten-Free Diet, Dietary Weight Reduction,
and Dietary Supplements on Psoriasis and Psoriatic Arthritis (PsA) (continued)
Source;













Intervention: n = 20;
control: n = 20.
12-wk
supplementation
with ω-3 fatty acids:
EPA capsules
(ReEPA) containing







Compared with controls, ω-3 group had significantly greater
and faster reduction in psoriasis severity. Specifically, ≥75%
reduction in clinical scorec (erythema, induration,
desquamation) in 45% of ω-3 group vs 15% of controls
(P < .05). ≥50% reduction in clinical score in 65% of ω-3 group
vs 55% of controls (NS). Mean (SD) duration to 50% reduction
in clinical score, 5.1 (1.5) wk ω-3 group vs 7.6 (3.4) wk










≤10, age 18-70 y, no
systemic/biologic
treatment for 4 wk or
topical treatment for 2
wk before study.
Intervention: n = 15;
control: n = 15.
8-wk
supplementation
with ω-3 fatty acids:
2 Oravex capsules
containing 560 mg
EPA, 80 mg DHA, 15







Compared with controls, ω-3 group had significantly greater
improvement in psoriasis severity, psoriatic nail severity,
dermatology quality of life, pruritus, and scalp psoriasis.
Specifically, mean PASI reduction, 6.8 ω-3 group vs 3.53
controls (P < .001). Mean NAPSI reduction, 1.23 ω-3 group vs 0
controls (P = .048). Mean DLQI reduction, 6.7 ω-3 group vs 3.0
controls (P = .006). Presence of pruritus reduction, 80% ω-3
group vs 40% controls (P < .001). Mean severity of scalp








with PsA, age 23-68 y,





with ω-3 fatty acids:
6 capsules
containing 1.12 g
EPA, 0.76 g DHA
daily
None Uncontrolled data: Supplementation with ω-3 resulted in
significant improvement in skin and arthritis disease severity
after 8 wk. Specifically, mean PASI, 3.56 at baseline, 1.98 at 4
wk (P < .001), 1.24 at 8 wk (P < .001). Mean pruritus, scaling,
induration, and erythema scores improved significantly from
baseline at weeks 4 and 8 (P < .01). Patient-reported severe
joint pain in 53% of patients with PsA at baseline, 6% at week









systemic treatment for 2
mo or topical treatment




with ω-3 fatty acids:
30 mL fish oil
(MaxEPA)
containing 5.4 g
EPA, 4.8 g DHA,




None Uncontrolled data: Supplementation with ω-3 resulted in
“moderate or excellent improvement” in psoriasis severity in
58% of patients, “mild improvement” in 19%, and “no change”
in 23% after 4 mo (degree of improvement vs baseline graded










(n = 24), generalized
pustular psoriasis
(n = 1), palmoplantar






with ω-3 fatty acids:
18 fish oil capsules
(Max EPA)
containing 3.2 g
EPA, 2.2 g DHA daily
None Uncontrolled data: Supplementation with ω-3 resulted in
minimal improvement in psoriasis severity in 35% of patients,
no change in 43%, and “mild worsening” in 22% after 6-8 wk
(minimal improvement is 1 point improvement in erythema,








12-69 y, no systemic
treatment for 2 mo or
topical treatment for 2
wk before study. N = 18.
4-mo
supplementation





EPA, 360 mg DHA,
3.36 g LA, 960 mg
GLA, vitamin E daily.
100 μg selenium
daily. Low-fat diet.
None Uncontrolled data: Supplementation with ω-3 and ω-6 resulted
in “moderate or excellent improvement” in psoriasis severity in
59% of patients, “mild improvement” in 23%, and “no change”
in 18% after 4 mo (degree of improvement vs baseline graded










13% with PsA, adults, no
systemic treatment for 2
mo or topical treatment




with ω-3 fatty acids:




EPA, 7-9 g DHA
daily. Exclusion of
fats and oils from
diet
None Uncontrolled data: Supplementation with ω-3 resulted in
significant reduction in erythema (P < .02), scaling (P < .001),














treatment. N = 10.
≥6-wk
supplementation
with ω-3 fatty acids:






None Uncontrolled data: Supplementation with ω-3 resulted in
“slight to moderate improvement” in psoriasis severity
(redness, scaling) in 80% of patients after 6 wk; “improvement”
was maintained for the duration of treatment
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Additional studies are needed to determine whether it is the type
of diet and/or weight reduction that reduces psoriasis severity, the
associated mechanisms, the amount of weight reduction needed for
clinical response, how to implement dietary recommendations ef-
fectively, and the role of exercise in conjunction with dietary weight
reduction.
Table 2. Interventional Studies on the Effects of Gluten-Free Diet, Dietary Weight Reduction,
and Dietary Supplements on Psoriasis and Psoriatic Arthritis (PsA) (continued)
Source;






Psoriasis, age 22-75 y,
topical treatment
continued. N = 9.
6-mo
supplementation
with ω-3 fatty acids:
3.6 g EPA daily
None Uncontrolled data: Supplementation with ω-3 resulted in
“clinically significant improvement” in psoriasis severity
(erythema, scaling, thickness) in 86% of patients after 6 mo
















18% with PsA, age 18-80
y, no systemic treatment
for 3 mo or topical
treatment for 7 d before
study. Intervention:




mL IV twice daily








Compared with ω-6 group, ω-3 group had significantly greater
reduction in psoriasis severity. Specifically, mean (SD) PASI
reduction, 11.2 (9.8) ω-3 group vs 7.5 (8.8) ω-6 group
(P = .048). PASI 50, 37% of ω-3 group vs 23% of ω-6 group.
Mean (SD) self-assessed severity VAS scorec reduction,












age 21-65 y, not
receiving systemic
treatment, no topical
treatment for 5 d before
study. Intervention:




mL IV twice daily








Compared with ω-6 group, ω-3 group had greater improvement
in all psoriasis severity measures (erythema, infiltration,
desquamation, patient-reported subjective score [daily life
impairment, pruritus, burn, pain]) (P < .05). All psoriasis













adults, no systemic or
topical treatment for 4 wk
before study. Interven-
tion: n = 20; control:
n = 21.
12-wk supplementa-
tion with vitamin D:
1 capsule containing





No significant differences between vitamin D and control groups in
improvement in psoriasis severity. Specifically, slight
improvement (<33% PASI reduction) in 45% of vitamin D group
vs 38% of controls. No change or increase in PASI, 55% of










PsA, treated with metho-
trexate 10 mg weekly and
NSAIDs for ≥3 mo before
study. Intervention: os-
teopenia, n = 10; control:
no osteopenia, n = 9.
6-mo supplementa-






Between-group comparisons were not reported. Significant im-
provement in arthritis disease severity (DAS28) in vitamin D group
(P = .048); no significant change in controls. No significant im-
provement in skin disease severity (PASI, patient’s global assess-








Plaque psoriasis or EP,
BSA ≥15%, age 19-76 y,
not responding to ≥1
standard treatment, no
systemic treatment or
phototherapy for 30 d or
topical treatment for 14 d
before study. N = 85.
6-mo to 3-y supple-
mentation with vita-
min D: mean (SD)
dose 2.1 (0.8) μg
calcitriol (Rocaltrol)
daily (dose adjusted




None Uncontrolled data: Supplementation with vitamin D resulted in
significant improvement in psoriasis severity after 6 mo and 3 y.
Specifically, mean (SD) PASI, 18.4 (1.0) at baseline, 9.7 (0.8) at
month 6, 7.0 (1.3) at year 3 (P < .001). Mean (SD) global severity
score (erythema, thickness, scaling), 7.7 (1.2) at baseline, 3.2
(1.0) at year 3 (P < .001). Erythema, scaling, thickness each de-












tion with vitamin D: 1
μg alfacalcidol
(Alfarol) daily
None Uncontrolled data: Supplementation with vitamin D resulted in
effective response in 76% of patients after 6 mo (effective re-
sponse is “moderate improvement,” “marked improvement,” or










treatment, age 22-63 y,
no psoriasis treatment for
2 wk before study.
N = 14.
≤1-y supplementa-





on urinary and serum
calcium levels). Di-
etary calcium limited
to 800 mg daily.
None Uncontrolled data: Supplementation with vitamin D resulted in
>25% improvement in psoriasis severity (lesion size, erythema,
scaling, pruritus) in 71% of patients, >50% improvement in 50%,








PsA, age 18-70 y, no
change in treatment for 3
mo before or during study








on urinary and serum
calcium levels)
None Uncontrolled data: Supplementation with vitamin D resulted in
significant improvement in tender joint count (P < .01) and
physician global assessment of arthritis activity (P < .05) after
6 mo; no significant change in patient global assessment, grip
strength, or patient-reported pain and physical activity scores
(AIMS)
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Table 2. Interventional Studies on the Effects of Gluten-Free Diet, Dietary Weight Reduction,
and Dietary Supplements on Psoriasis and Psoriatic Arthritis (PsA) (continued)
Source;




















None Uncontrolled data: Supplementation with vitamin D resulted in
significant improvement in psoriasis severity (PASI) in all
patients after 6 mo (P = .002). Lower psoriasis severity (PASI)
was








Psoriasis, BSA >25%, age
28-65 y, no psoriasis
















None Uncontrolled data: Supplementation with vitamin D resulted in
“marked improvement” in scale, erythema, and thickness in
13% of patients, “moderate improvement” in 13%, “mild
improvement” in 38%, and “no improvement” in 38% after 6
mo; supplementation resulted in “marked improvement” in
area of involvement in 13% of patients, “mild improvement” in








treatment, age 37-63 y,
topical steroids
continued. N = 7.
6-mo
supplementation
with vitamin D: 1 μg
alfacalcidol (Alfarol)
daily
None Uncontrolled data: Supplementation with vitamin D resulted in
complete remission of psoriasis in 29% of patients, marked
improvement in 29%, and no change in 43% after 6 mo
(complete remission is complete flattening of plaques, area
improved ≥95%; marked improvement is nearly











Severe EP or PsA
inpatients, adults.
Intervention:
n = 14 (EP),
n = 15 (PsA). Control:
n = 14 (EP),
n = 15 (PsA).
30-d
supplementation





























Compared with PsA and EP controls, PsA and EP selenium
groups had significantly lower overall psoriasis severity after
supplementation. Specifically, mean (SD) severity scorec
(plaque desquamation, plaque hyperemia, plaque inflammation,
nail dystrophy, joint pain) at day 30, 1.9 (0.1) PsA selenium
group vs 6.8 (0.2) PsA controls (P < .001); 4.0 (0.1) EP
selenium group vs 6.2 (0.1) EP controls (P < .05). Mean (SD)
PASI at day 30, 16 (6) PsA selenium group vs 29 (10) PsA
controls (P value not reported); 19 (4) EP selenium group vs











18-50 y, skin type II or
III, nonsmokers for ≥2 y,
no selenium
supplementation for 6
mo or topical treatment
for 1 wk before study.
Intervention: n = 19,























No significant differences between selenium and control groups
in improvement in psoriasis severity at the end of
supplementation or after the follow-up period. Specifically,
PASI 75 at wk 4, 47% of selenium group vs 56% of controls
(P > .05). PASI 75 at wk 8, 58% of selenium group vs 56% of
controls (P > .05). Mean (SD) PASI at baseline, wk 4, wk 8,
13.02 (6.25), 3.59 (2.27), 2.82 (2.48) selenium group vs
12.37 (4.71), 2.34 (1.70), 2.23 (1.49) controls (significant





























No significant differences between selenium and control groups
in proportion of patients with improved psoriasis severity after
2 or 4 wk. Specifically, PASI 50 at wk 2, 54% of selenium group
vs 82% of controls (P > .05). PASI 75 at week 4, 45% of
selenium group vs 82% of controls (P > .05).
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Weight reduction should always be recommended for over-
weight patients because it has beneficial effects on other health out-
comes including reduction of cardiometabolic and certain cancer risks.
At this time, data are lacking on dietary weight reduction in normal-
weight patients with psoriasis.
Recommendation 2: Dietary Weight Reduction in Psoriasis
• In overweight or obese adults with psoriasis (BMI, 25), we
strongly recommend dietary weight reduction with a hypocaloric
diet as an adjunctive intervention to standard medical therapies
for psoriasis.
• This strong recommendation (strength 1) is based on level A evi-
dence, with consistent results among included studies and agree-
ment with systematic reviews and meta-analysis.4,9,19-23
Question 3: Are Any Dietary Supplements Helpful
in Psoriasis?
Dietary supplements are used by a significantly higher proportion
of patients with psoriasis than those without psoriasis.29 Many
patients with psoriasis believe that supplementation can improve
their disease severity.5 Patients most frequently report improve-
ment from supplementation with fish oil and vitamin D.5 How-
ever, patients should consult with a health care practitioner
Table 2. Interventional Studies on the Effects of Gluten-Free Diet, Dietary Weight Reduction,
and Dietary Supplements on Psoriasis and Psoriatic Arthritis (PsA) (continued)
Source;









21-52 y, no systemic
treatment for 2 y or
topical treatment for 2













None Uncontrolled data: Supplementation with selenium resulted in
“some improvement” in psoriasis severity in 29% of patients,
“slight worsening” in 29%, and “severe worsening” in 14%













Psoriasis, age >12 y,
using various topical
treatments.
Intervention: n = 36;
control: n = 35
3-wk treatment with
vitamin B12: 1000











No differences between vitamin B12 and control groups in
proportion of patients with improved psoriasis severity after 3
or 6 wk (reports that lack of treatment effect is “evident
without formal statistical analysis”). Specifically, “substantially
improved or clear” in 8% of vitamin B12 group vs 14% of
controls at week 3; 61% of vitamin B12 group vs 60% of
















dose of vitamin B12.
None Uncontrolled data: Treatment with vitamin B12 resulted in
changes in psoriasis severity of “eruption involuted” in 32% of
patients, “improved 75%-80%” in 29%, “slowly improving” in
18%, “no results” in 15%, and “slight recurrence after










psoriasis, PASI >10, age
20-50 y, no
methotrexate for 2 mo
before study.
Intervention: n = 17;











vitamins A, D, E, K,








Compared with controls, micronutrient group had significantly
greater reduction in psoriasis severity (PASI) after
supplementation (P = .045). PASI 75, 65% of micronutrient
group vs 35% of controls (P = .08). Mean (SD) PASI improved
from 31.80 (10.57) at baseline to 5.50 (3.82) at week 12
micronutrient group (P = .001); from 30.23 (10.87) to
10.86 (9.84) controls (P = .001)
Abbreviations: AGA, antigliadin antibodies; AIMS, Arthritis Impact
Measurement Scales; BMI, body mass index, calculated as weight in kilograms
divided by height in meters squared; BSA, body surface area; DAS28, 28-joint
Disease Activity Score; DAS28-CRP, 28-joint Disease Activity Score (C-reactive
protein); DHA, docosahexaenoic acid; DLQI, Dermatology Life Quality Index;
DMARDs, disease-modifying antirheumatic drugs; DPA, docosapentaenoic acid;
EP, erythrodermic psoriasis; EPA, eicosapentaenoic acid; GLA, γ-linolenic acid;
HR, hazard ratio; IM, intramuscular; IV, intravenous; LA, linoleic acid; LEI, Leeds
Enthesitis Index; MDA, minimal disease activity; NAPSI, Nail Psoriasis Severity
Index; NB-UVB, narrowband UVB;
NS, nonsignificant; NSAIDs, nonsteroidal anti-inflammatory drugs; PASI,
Psoriasis Area and Severity Index; plus sign, positive; SPARCC, Spondyloarthritis
Research Consortium of Canada Enthesitis Index; tTG, tissue transglutaminase;
VAS, visual analogue scale.
a These 2 articles report different outcome measures from the same study.
b Follow-up of subset of patients from Jensen et al,23 2013; intervention group
entered maintenance period, control group first crossed over to 16-week
hypocaloric diet then entered maintenance period.
c Higher score corresponds to greater disease severity.
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 In adults with psoriasis with confirmed celiac disease, we strongly recommend
a gluten-free diet.
1 A Rubio-Tapia et al,17
2013
 Only in adults with psoriasis who test positive for serologic markers of gluten
sensitivity, we recommend a 3-mo trial of a gluten-free diet as an adjunctive
intervention to standard medical therapies for psoriasis.





X We do not recommend universal screening for serologic markers of gluten
sensitivity among adults with psoriatic diseases because of a high rate of
false-positive results. Based on recommendations from the American College of
Gastroenterology, patients who are candidates for screening include those with




 In overweight or obese adults with psoriasis (BMI ≥25), we strongly recommend
dietary weight reduction with a hypocaloric diet as an adjunctive intervention to
standard medical therapies for psoriasis.
1 A Al-Mutairi and
Nour,19 2014;
Gisondi et al,20
2008; Guida et al,21
2014; Jensen




X We do not recommend oral fish oil supplementation for treatment of psoriasis in
adults because oral fish oil was not effective at the examined doses and
durations.
… Because evidence is limited regarding the effectiveness of intravenous fish oil




X We do not recommend oral vitamin D supplementation for prevention or
treatment of psoriasis in adults with normal vitamin D levels.
3c. Selenium
supplementation
X We do not recommend selenium supplementation for treatment of plaque
psoriasis in adults.
… Because evidence is limited regarding the effectiveness of selenium
supplementation on erythrodermic psoriasis in adults, a recommendation cannot
be made at this time.
3d. Vitamin B12
supplementation




… Because evidence is limited regarding the effectiveness of combination
micronutrient supplementation on psoriasis in adults, a recommendation cannot




 Based on low-quality evidence, adults with psoriasis may consider a trial of a
Mediterranean diet and consuming extra virgin olive oil as the main culinary
lipid, ≥2 servings of vegetables daily, ≥3 servings of fruits daily, legumes ≥3
times weekly, fish or seafood ≥3 times weekly, tree nuts ≥3 times weekly, or
sofrito sauce (tomatoes, onions, garlic, olive oil) ≥2 times weekly.
2B C Barrea et al,60 2015
 Based on low-quality evidence, adults with psoriasis may consider a trial of
consuming more ω-3 PUFAs, monounsaturated fatty acids, fiber, or complex
carbohydrates and consuming less total energy, saturated fatty acids, total
PUFAs, ω-6 PUFAs, ω-6:ω-3 PUFA ratio, or simple carbohydrates.




 In overweight or obese adults with psoriatic arthritis (BMI ≥25), we recommend
dietary weight reduction with a hypocaloric diet as an adjunctive intervention to
standard medical therapies for psoriatic arthritis.
2A B Di Minno et al,62
2014
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before taking supplements because many supplements have
adverse effects or contraindications.
ω-3 Fatty Acids (Fish Oil)
Polyunsaturated fatty acids (PUFAs), a type of dietary fatty acids,
include ω-3 and ω-6 PUFAs. The ω-6 PUFAs arachidonic acid
and linoleic acid are metabolized into leukotriene B4 (LTB4); LTB4
is an inflammatory mediator that is elevated in psoriatic plaques.30,31
In contrast, metabolites of ω-3 PUFAs oppose the pro-inflamma-
tory effects of LTB4.32
Whereas the typical Western diet has an ω-6:ω-3 ratio
of 15-20:1, an ideal ratio of 1.8:1 is recommended by an interna-
tional panel of experts.31 This ratio is similar to that found
throughout human history. Notably, lower psoriasis incidence is
seen in regions with a higher relative intake of ω-3 PUFAs.31 Oil
derived from cold-water fish is rich in ω-3 PUFAs, including
eicosapentaenoic acid (EPA) and docosapentaenoic acid (DHA).30
Studies evaluating the use of oral fish oil supplementation in pso-
riasis show conflicting results. Accurately assessing study quality is
paramount when trial results differ and wheremeta-analyses are not
possible due to heterogeneity of outcomes. Double-blind RCTs are par-
ticularly helpful in minimizing assessment bias. Among 9 double-
blind RCTs,12,30,33-39 oral supplementation with fish oil was shown to
be ineffective in reducing psoriasis severity in 7 of 9 trials; these data
are based on 449 patients enrolled in trials showing no benefit and
48 patients in trials showing benefit. The duration of supplementa-
tion in these trials ranged from 14 days to 7 months, and the daily dos-
age of EPA and DHA varied from 0.216 to 5.4 g and 0.132 to 3.6 g, re-
spectively.
However, with regard to intravenous fish oil supplementa-
tion, 2 double-blind RCTs with a pooled population of 103
patients showed beneficial effects in reducing psoriasis
severity.40,41 The duration of supplementation in these trials
ranged from 10 to 14 days, and the daily intravenous dosage of
both EPA and DHA varied from 2.1 to 4.2 g.
Recommendation 3a: Fish Oil Supplementation
in Psoriasis
• We do not recommend oral fish oil supplementation for treat-
ment of psoriasis in adults because oral fish oil was not effective
at the examined doses and durations.
• Because evidence is limited regarding the effectiveness of intra-
venous fish oil supplementation on psoriasis in adults, a recom-
mendation cannot be made at this time.
Vitamin D
Vitamin D can be given in different forms including cholecalcif-
erol, alfacalcidol, and calcitriol.8 While topical vitamin D is well
established as an effective treatment option in psoriasis, the ben-
efit of oral supplementation is less certain. Vitamin D deficiency is
common in patients with psoriasis,42 and lower levels of serum
vitamin D are associated with higher psoriasis severity.43 How-
ever, data are lacking regarding the effects of vitamin D supple-
mentation on psoriasis severity in vitamin D–deficient patients.
Overall, high-quality evidence is lacking to support the use of vi-
tamin D supplementation in psoriasis. Controlled studies show no ben-
efit of vitamin D supplementation for improving skin disease sever-
ity over a period of 3 to 6 months.44,45 In comparison, some studies
show that improvement in skin disease severity can be seen after vi-
tamin D supplementation over a period of 6 months or longer in pa-
tients with plaque or erythrodermic psoriasis.46-50 However, this is
based entirely on uncontrolled data. In addition, to date, there is no
clear evidence to support one form of vitamin D over another.
In individuals without a history of psoriasis, vitamin D intake
appears to have no impact on the development of psoriasis.51
Recommendation 3b: Vitamin D Supplementation
in Psoriasis
• We do not recommend oral vitamin D supplementation for pre-
vention or treatment of psoriasis in adults with normal vitamin D
levels.
Selenium
Selenium is an essential nutrient that can affect the immune
system.52 Decreased selenium levels can be seen in patients with
psoriasis,52 and low selenium concentrations may be associated
with longer disease duration.53
Based on the available literature, selenium supplementation has
varying results in patients with different subtypes of psoriasis.52,54-56







 In adults with psoriatic arthritis, we recommend a trial of oral vitamin D
supplementation (0.5 μg alfacalcidol or 0.5-2.0 μg calcitriol daily) as an
adjunctive intervention to standard medical therapies for psoriatic arthritis.
2A B Gaál et al,45 2009;
Huckins et al,63
1990
… Because evidence is limited regarding the effectiveness of selenium
supplementation on psoriatic arthritis in adults, a recommendation cannot
be made at this time.
X We do not recommend fish oil supplementation for treatment of psoriatic
arthritis in adults.
Abbreviations: BMI, body mass index, calculated as weight in kilograms divided
by height in meters squared; check mark, positive recommendation, with
strength of recommendation indicated by number of check marks; ellipses,
neither positive nor negative recommendation; X, negative recommendation.
a Level of evidence determines the grade of recommendation.13 Level of
evidence “A” refers to high-quality, patient-oriented evidence, which leads to a
“strong recommendation” (strength of recommendation 1). Level of evidence
“B” refers to limited-quality, patient-oriented evidence, which leads to a “weak
recommendation” (strength of recommendation 2A). Level of evidence “C”
refers to low-quality evidence, which leads to a “weak recommendation”
(strength of recommendation 2B).
b Table exclusively includes sources from the highest level of evidence
supporting the corresponding strength of recommendation.
Clinical Review & Education Review Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis
946 JAMA Dermatology August 2018 Volume 154, Number 8 (Reprinted) jamadermatology.com
© 2018 American Medical Association. All rights reserved.
Downloaded From:  by a New York Medical College User  on 11/06/2018
Specifically, in 1 small study (n = 28) evaluating inpatients with eryth-
rodermic psoriasis, selenium supplementation with a combination
of 48 μg selenium aspartate, 50 mg coenzyme Q10 (ubiquinone ac-
etate), and 50 mg vitamin E (α-tocopherol) daily seemed to be ben-
eficial in conjunction with conventional therapy.54
However, selenomethionine supplementation provides no
benefit in patients with plaque psoriasis either as monotherapy or
in combination with phototherapy or topical therapy.52,55,56
Recommendation 3c: Selenium Supplementation
in Psoriasis
• We do not recommend selenium supplementation for treatment
of plaque psoriasis in adults.
• Because evidence is limited regarding the effectiveness of sele-
nium supplementation on erythrodermic psoriasis in adults, a rec-
ommendation cannot be made at this time.
Vitamin B12
Based on the available literature, Vitamin B12 supplementation
appears to be ineffective as a therapeutic intervention in
psoriasis.57,58 When compared with patients treated with pla-
cebo, intramuscular high-dose vitamin B12 was shown to be
ineffective.58
Recommendation 3d: Vitamin B12 Supplementation
in Psoriasis
• We do not recommend vitamin B12 supplementation for treat-
ment of psoriasis in adults.
Micronutrients
Combination micronutrient supplementation may be beneficial in
plaque psoriasis. Specifically, compared with patients with psoria-
sis treated with low-dose methotrexate alone, those receiving
supplementation with a combination of vitamins and minerals (fo-
lic acid, magnesium, iron, zinc, copper, manganese, selenium, chro-
mium, iodine, and vitamins A, D, E, K, C, B1, B2, B3, B6, and B12) for 3
months in conjunction with low-dose methotrexate had signifi-
cantly greater improvement in psoriasis severity.11 However, this is
based on 1 small study (n = 34).
Recommendation 3e: Micronutrient Supplementation
in Psoriasis
• Because evidence is limited regarding the effectiveness of com-
bination micronutrient supplementation on psoriasis in adults, a
recommendation cannot be made at this time.
Question 4: Are There Any Specific Foods, Nutrients,
or Dietary Patterns That Are Helpful or Harmful in Psoriasis?
A large proportion of patients with psoriasis report having tried a
special diet for their psoriasis,5 and a majority of patients believe
that diet regimen can improve psoriasis.27 Although multiple
observational studies exist evaluating the dietary patterns of
patients with psoriasis,5,59-61 data demonstrating a relationship
with disease severity is limited. In general, the dietary patterns of
patients with psoriasis appear to be different from those of
patients without psoriasis (Table 1). The contribution of certain
foods, nutrients, and dietary patterns to psoriasis severity varies,
which leads to the following recommendation.60,61 Additional
data from patient experiences help inform this topic5,27; however,
these observations are exploratory and subject to reporting bias.
Recommendation 4: Specific Foods, Nutrients,
or Dietary Patterns in Psoriasis
• Based on low-quality evidence, adults with psoriasis may con-
sider a trial of a Mediterranean diet and consuming extra virgin ol-
ive oil as the main culinary lipid, at least 2 servings of vegetables
daily, at least 3 servings of fruits daily, legumes at least 3 times
weekly, fish or seafood at least 3 times weekly, tree nuts at least 3
times weekly, or sofrito sauce (tomatoes, onions, garlic, olive oil)
at least 2 times weekly.60
• Based on low-quality evidence, adults with psoriasis may con-
sider a trial of consuming more ω-3 PUFAs, monounsaturated fatty
acids, fiber, or complex carbohydrates and consuming less total en-
ergy, saturated fatty acids, total PUFAs, ω-6 PUFAs, ω-6:ω-3 PUFA
ratio, or simple carbohydrates.61
• This weak recommendation (strength 2B) is based on level C
evidence.60,61
Question 5: Are Any of These Dietary Interventions Useful
for Patients With Psoriatic Arthritis?
Psoriatic arthritis affects approximately one-third of patients with
psoriasis.2 Determining the effects of dietary interventions on
psoriatic arthritis severity is important for overall disease
management.
Gluten-Free Diet
All of the studies on gluten-free diet include patients with psoriatic
arthritis but do not assess arthritis disease severity or report out-
comes separately in these patients.14-16 Therefore, it remains un-
known whether gluten-free diet can help improve psoriatic arthri-
tis severity.
Dietary Weight Reduction
Dietary weight reduction with a hypocaloric diet seems to be help-
ful in overweight and obese (BMI, 25) patients with psoriatic ar-
thritis. Specifically, patients starting treatment with tumor necro-
sis factor blockers (etanercept, adalimumab, or infliximab) are
significantly more likely to achieve minimal arthritis disease activ-
ity and to experience weight loss after a 6-month hypocaloric diet
than after a regular diet.62
Dietary Supplements
Whereas oral vitamin D supplementation seems to be ineffective in
improving skin disease severity, it may be beneficial in psoriatic ar-
thritis. Specifically, uncontrolled studies show that 0.5 μg alfacal-
cidol or 0.5 to 2.0 μg calcitriol daily for 6 months leads to signifi-
cant improvement in arthritis disease severity.45,63
In 1 small study (n = 30) evaluating inpatients with psoriatic ar-
thritis, a combination of 48 μg selenium aspartate, 50 mg coen-
zyme Q10 (ubiquinone acetate), and 50 mg vitamin E (α-tocopherol)
daily seemed to be beneficial in conjunction with conventional
therapy.54
Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis Review Clinical Review & Education
jamadermatology.com (Reprinted) JAMA Dermatology August 2018 Volume 154, Number 8 947
© 2018 American Medical Association. All rights reserved.
Downloaded From:  by a New York Medical College User  on 11/06/2018
Based on the literature, we determine fish oil supplementa-
tion to be ineffective in psoriatic arthritis. Compared with control
patients, patients supplementing with fish oil do not experience
s i g n i f i c a n t l y g r e a t e r i m p r ove m e n t i n a r t h r i t i s d i s e a s e
severity.12,33,34
There are no data on vitamin B12 or combination micronutri-
ent supplementation in psoriatic arthritis.
Specific Foods, Nutrients, or Dietary Patterns
There are no data to support specific foods, nutrients, or dietary
patterns in psoriatic arthritis.
Recommendation 5: Dietary Interventions
in Psoriatic Arthritis
• In overweight or obese adults with psoriatic arthritis (BMI,
25), we recommend dietary weight reduction with a hypocal-
oric diet as an adjunctive intervention to standard medical
therapies for psoriatic arthritis.
• In adults with psoriatic arthritis, we recommend a trial of oral
vitamin D supplementation (0.5 μg alfacalcidol or 0.5-2.0 μg cal-
citriol daily) as an adjunctive intervention to standard medical
therapies for psoriatic arthritis.
• Because evidence is limited regarding the effectiveness of sele-
nium supplementation on psoriatic arthritis in adults, a recom-
mendation cannot be made at this time.
• We do not recommend fish oil supplementation for treatment of
psoriatic arthritis in adults.
• These weak recommendations (strength 2A) are based on
level B evidence; limitations include a lack of randomization,45
uncontrolled data,45,63 and study-related bias.45
Discussion
In this article, we made evidence-based recommendations on the
impact of diet in adults with psoriatic diseases. We highlight 3 con-
cepts important for interpreting these recommendations. First, it is
universally important to continue regular medical treatment for pso-
riatic diseases. We do not recommend relying on dietary interven-
tions as the sole source of treatment. Second, dietary interven-
tions can be associated with adverse effects and contraindications.
Third, these dietary recommendations may have impact beyond pa-
tients’ skin and joints and may affect one’s general health.5,64,65
The findings of this systematic review are dependent on the
strength of the primary literature. Some studies are not random-
ized, blinded, or controlled, which may introduce bias. There is
heterogeneity among studies with regard to populations studied,
interventions used, and outcomes measured.
Conclusions
Dietary interventions, when implemented, should be used in con-
junction with standard medical therapies for psoriatic diseases. We
strongly recommend dietary weight reduction with a hypocaloric diet
in overweight and obese patients with psoriasis. We weakly recom-
mend a gluten-free diet only in patients who test positive for sero-
logic markers of gluten sensitivity. Based on low-quality data, se-
lect foods, nutrients, and dietary patterns may affect psoriasis. For
patients with psoriatic arthritis, we weakly recommend vitamin D
supplementation and dietary weight reduction with a hypocaloric
diet in overweight and obese patients.
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